Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Heart failure, a chronic condition characterized by the heart's inability to pump enough blood to meet the body's oxygen and blood demands, manifests in symptoms like fatigue, shortness of breath, and occasional coughing. This condition significantly impedes daily activities such as walking, climbing stairs, or carrying heavy objects. Several factors are propelling the growth of the heart failure market, including the rising prevalence of cardiovascular disorders, an expanding geriatric population, and evolving lifestyle habits like unhealthy dietary patterns, excessive alcohol consumption, smoking, obesity, and physical inactivity, which increase the risk of arrhythmia and heart failure.
Additionally, a robust pipeline of promising therapies and product approvals are further fuelling market growth. Despite these positive developments, the heart failure market faces challenges posed by severe side effects associated with certain treatments. These side effects can deter patients from adhering to prescribed therapies, hindering their efficacy and overall treatment outcomes. Rising Prevalence of Cardiovascular Disorders: The increasing incidence of cardiovascular diseases, a major risk factor for heart failure, is significantly driving market growth.
The aging population, with their higher susceptibility to heart failure, is contributing to the market's expansion. The growing prevalence of unhealthy lifestyle habits, including poor diet, excessive alcohol consumption, smoking, obesity, and physical inactivity, is increasing the risk of heart failure and driving market demand. The development of novel therapies and the approval of new products are fuelling market growth and providing patients with more treatment options. The potential for severe side effects associated with certain heart failure treatments can deter patients from adhering to their medication regimens, hindering treatment effectiveness and overall patient outcomes.
To overcome the challenge of severe side effects, researchers and pharmaceutical companies are focusing on developing safer and more effective therapies that minimize adverse effects while maintaining efficacy. Additionally, patient education and counselling can play a crucial role in improving medication adherence and treatment outcomes. The heart failure market, driven by a combination of rising disease prevalence, lifestyle factors, and a robust pipeline of therapies, is poised for continued growth. However, addressing the challenge of severe side effects remains crucial to ensuring optimal patient outcomes and sustainable market growth.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Size Value In 2022 | USD 12.28 Billion |
| Growth Rate | 5.9% (2023-2032) |
Heart Failure Drugs Market Highlights:
Global Heart Failure Drugs Market Overview
Heart Failure Drugs Market Size was valued at USD 11.6 billion in 2021 and is projected to grow from USD 12.28 Billion in 2022 to USD 20.57 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.9% during the forecast period (2023 - 2032). Rising cardiovascular disorders and developments of several heart failure drugs are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Heart Failure Drugs Market Trends
- Robust pipeline of drugs under development to boost market growth
A major driver of the growth of the heart failure drugs market is the strong drug pipeline under development. For instance, furosemide injection (SCP-101), sponsored by Johns Hopkins University in collaboration with his Scpharmaceuticals Inc., went into Phase 2 clinical trials in 2015. This injection is indicated for the treatment of heart failure. Furosemide and azosemide, sponsored by Hyogo College of Medicine, completed Phase 4 clinical trials in 2016. These drugs are used to treat heart failure. Sponsored by Otsuka Pharmaceutical Co., Ltd., tolvaptan was in Phase 3 clinical trials in 2016, and the drug is indicated for the treatment of heart failure in children.
Further, approval of new drugs by the Food and Drug Administration (FDA) is also expected to fuel the growth of the congestive heart failure drugs market. In 2016, the FDA approved his Byvalson from Ireland-based company, Allergan. This drug is used to treat high blood pressure. In 2015, the FDA approved Corlanor (ivabradine) from US-based company Amgen Inc. This drug treats chronic heart failure. In addition, rising geriatric population, unhealthy lifestyle, and growing awareness of chronic disease management are boosting the heart failure drugs market CAGR.
Due to the increasing work pressure and stress of the younger generation, the problem of heart failure disease is also increasing. People belonging to the elderly group already have many cardiovascular diseases, which will help boost the heart failure drugs market significantly. Even small changes in cardiovascular rhythms and velocities contribute to the significant growth of the cardiovascular drug market. Not only the elderly, but also the younger generation have many lifestyle-related cardiovascular diseases. Therefore, the heart failure Drugs Market has increased significantly with the prevalence of cardiac arrest among the people. However, the change in lifestyle such as excessive alcohol consumption, smoking and unhealthy diet habits causes heart problems is another factor driving the growth of the Heart Failure Drugs market revenue.
Heart Failure Drugs Market Segment Insights
Heart Failure Drugs Type Insights
The Heart Failure Drugs market segmentation, based on type, includes Beta-Blockers, ACE Inhibitors, Angiotensin-Receptor Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Diuretic. The ACE inhibitors Heart Failure Drugs segment held the majority share in 2021 contribution to around in respect to the Heart Failure Drugs market revenue. ACE inhibitors prevent the formation of angiotensin, which causes blood vessels to constrict, and beta blockers block the actions of certain chemicals. ACE inhibitors are mainly used in the treatment of heart failure. These agents decrease the formation of angiotensin II, thereby decreasing both arteriolar and venous resistance.
Heart Failure Drugs End Users Insights
Based on End Users, the Heart Failure Drugs industry has been segmented into Hospitals, and specialty centers. Hospitals have seen the highest growth due to rapid demand and supply of cardiovascular drugs due to the ready availability of rare and commonly used drugs. Cardiovascular emergency medicines are readily available in hospital pharmacies, but pharmacies are very expensive and only available in hospitals.
Specialty centers is the next fastest growing segment due to that it provides specialty services focusing on specific business needs, including assistance relating. The ability to directly compare other available medicines also helps consumers to choose the right medicine.
August 2021 the Eli Lilly and Company announced that the US FDA had approved Jardiance (empagliflozin) 10 mg to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with HFrEF.
Figure 2  Heart Failure Drugs Market, by End Users, 2021 & 2030 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Heart Failure Drugs Regional Insights
By Region, the study provides the market insights for Heart Failure Drugs into North America, Europe, Asia-Pacific and Rest of the World. North America Heart Failure Drugs market accounted for USD 5.01 billion in 2021 and is expected to exhibit a significant CAGR growth of 43.20% during the study period. This is attributed to the rise in the rate of cardiovascular disorders, increasing obesity cases among people and growing healthcare expenditure across the region.
Further, the major countries studied in the market report for Heart Failure Drugs are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 HEART FAILURE DRUGS MARKET SHARE BY REGION 2021 (%)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Heart Failure Drugs market accounts for one of the largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, and an increase in incidence of heart failure. Further, the Germany Heart Failure Drugs market held the largest market share, and the UK Heart Failure Drugs market was the fastest growing market in the European region.
The Asia-Pacific Heart Failure Drugs Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to growing patient pool, initiatives by the government to enhance quality of healthcare, rise in cardiovascular disorder cases and increase in disposable income. For instance, Australia's anticipated prevalence rate of CHF in 2020 ranged from 1.2% to 5.3%, primarily as a result of the nation's rising rates of diabetes and obesity. Moreover, China Heart Failure Drugs market held the largest market share, and the India Heart Failure Drugs market was the fastest growing market in the Asia-Pacific region.
Heart Failure Drugs Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Heart Failure Drugs market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments for Heart Failure Drugs such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Heart Failure Drugs industry escalating demand for effective drugs and treatment and their approval from authorized agencies to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the  Heart Failure Drugs industry to the expansion of pharmacies in hospitals and residential areas and the burgeoning e-commerce industry providing easy availability of medicines at affordable rates and the facility of secured online payment methods. In recent years, Heart Failure Drugs industry has provided medicine with some of the most significant benefits. The Heart Failure Drugs market major player such as Amgen Inc. (US), AstraZeneca (UK), Novartis AG (Switzerland), and others are working to expand the market demand by investing in research and development activities.
AstraZeneca is focused on the discovery, development and commercialization of prescription medicines in the areas of oncology and biopharmaceuticals, including cardiovascular heart disease. In May 2020, in order to lower the risk of cardiovascular (CV) death and heart failure hospitalisation in individuals with heart failure (NYHA classes II–IV) and decreased ejection fraction (HFrEF) both with and without type 2 diabetes, AstraZeneca's Farxiga (dapagliflozin) was approved in the US (T2D).
Also, Novartis AG uses innovative science and technology to address some of society's toughest health problems. Find new ways to deliver and develop treatments and make them available to as many people as possible. Novartis Entresto tablets, formerly known as LCZ696, reduce the risk of cardiovascular death and heart failure hospitalization in patients with chronic heart failure (NYHA classes II-IV) and reduced ejection fraction (HFrEF). It is usually given in combination with other heart failure treatments instead of an ACE inhibitor or another angiotensin receptor blocker (ARB). A low ejection fraction means the heart is not contracting with enough force, resulting in less blood being pumped out. In February 2019, Blackstone's Life Sciences and Novartis AG launched Anthos Therapeutics to develop drugs for cardiovascular heart failure.
Key Companies in the Heart Failure Drugs market includes
- Amgen Inc. (US)
- AstraZeneca (UK)
- Novartis AG (Switzerland)
- Boehringer Ingelheim International GmbH (Germany)
- Johnson & Johnson Services
- (UK)
- Bristol-Myers Squibb Company (US)
Heart Failure Drugs Industry Developments
February 2022Â Empagliflozin's (Jardiance) label was expanded to include treatment for CHF. These SGLT2 inhibitor medications showed a 35% decrease in hospitalisation and strong cardioprotective benefits in clinical studies. Additionally, the medication class has shown clinical value in managing CHF in patients without diabetes.
February 2021Â Forxiga, a medication used to treat adult heart failure with or without type-2 diabetes, has been approved in China, according to AstraZeneca.
January 2019Â The FDA disclosed the approval granted regarding the addition of a disease indication which related to the prevention against the occurrence of VTE in acutely sick medical patients who were hospitalized, at risk. Thromboembolic complications were noticed in them. But no high risk was announced regarding bleeding, for rivaroxaban which is a Janssen Pharmaceutical product.
January 2019Â An Indian business named Natco Pharma announced the release of the cardiovascular medicine valsartan-sacubitril, which is used to treat congestive heart failure. Valsartan-sacubitril is covered by a patent held by Novartis AG in India under the trade name Vymada.
Heart Failure Drugs Market Segmentation
Heart Failure Drugs Type Outlook
- Beta-Blockers
- ACE Inhibitors
- Angiotensin-Receptor Neprilysin Inhibitors
- Angiotensin Receptor Blockers
- Diuretic
Heart Failure Drugs End-User Outlook
- Hospitals
- Specialty Centers
Heart Failure Drugs Regional Outlook
-
North America- US
- Canada
-
Europe- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
-
Rest of the World- Middle East
- Africa
- Latin America
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
